Navigation Links
TGen-Scottsdale Healthcare clinical trial results for BIND-014 presented at AACR 2013
Date:4/10/2013

WASHINGTON, D.C. April 9, 2013 The nanoparticle drug BIND-014 is effective against multiple solid tumors, according to results generated by the Translational Genomics Research Institute (TGen) and Scottsdale Healthcare, and presented today at the American Association for Cancer Research (AACR) Annual Meeting 2013.

Data for the study was generated at the Virginia G. Piper Cancer Center Clinical Trials, a partnership of TGen and Scottsdale Healthcare.

Dr. Daniel Von Hoff, TGen Physician-In-Chief and Chief Scientific Officer of Scottsdale Healthcare's Clinical Research Institute, will present A Phase 1 Study of BIND-014, a PSMA-targeted Nanoparticle Containing Docetaxel, in Patients with Refractory Solid Tumors during an AACR session at 1 p.m. EDT today at the Washington, D.C., Convention Center, Room 146.

Dr. Von Hoff, the study's Principal Investigator, will present complete Phase 1 clinical data of BIND-014, which is produced by BIND Therapeutics, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called AccurinsTM. BIND-014 is the company's lead drug candidate.

In 28 patients with advanced or metastatic solid tumors, BIND-014 with its targeted docetaxel Accurin was shown to be generally safe and well-tolerated at the established maximum dose of 60 mg/m2. BIND-014 showed encouraging signs of anti-tumor activity, including one complete response, three partial responses and five patients with stable disease lasting at least four, 12-week-plus cycles. In addition, the pharmacokinetic (PK) profile of BIND-014 was substantially different from the published PK of conventional docetaxel.

"This Phase 1 trial has successfully established the safety and tolerability profile and maximum tolerated dose of BIND-014 in patients with advanced or metastatic solid tumor cancers," said Dr. Von Hoff, F.A.C.P., TGen's Distinguished Professor. "There is a cri
'/>"/>

Contact: Steve Yozwiak
syozwiak@tgen.org
602-343-8704
The Translational Genomics Research Institute
Source:Eurekalert

Page: 1 2 3

Related biology technology :

1. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
2. Bayer HealthCares Cotavance® Drug Eluting Balloon With Paccocath® Technology Reduced Five-Year Target Lesion Revascularization Rates by 59 Percent in PAD Patients Compared to Those Treated With Uncoated Balloon
3. Organovo to Present at Lazard Capital Markets 8th Annual Healthcare Conference
4. Pharmasset to Present at the Lazard Capital Markets Healthcare Conference
5. Sequenom Announces Participation at the 23rd Annual Piper Jaffray Healthcare Conference
6. SuperNova Diagnostics® to Present at the 23rd Annual Piper Jaffray Healthcare Conference in New York City
7. diaDexus, Inc. to Present at the Canaccord Genuity Healthcare Conference
8. ViroPharma to Participate in Two December Healthcare Investor Conferences
9. Celebrating 65 Years of Providing Superior Healthcare Products, Mission Pharmacal Continues to Thrive
10. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
11. Uroplasty to Present at the Oppenheimer 22nd Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... DC (PRWEB) January 14, 2014 Carahsoft ... for Thursday, January 23, 2014 at 2pm EST (11am ... Knowledge.” The topic focuses on how technology can turn ... critical decisions for government agencies. The online webinar will ...
(Date:1/14/2014)... pet owners drew up their lists of New Year,s resolutions for ... of my furry companion." Nowadays there are pet salons, dog and ... take the little canine or feline darlings along wherever mommy or ... pricey toys at the pet store. But anyone who has ever ...
(Date:1/14/2014)... BETHESDA, Md. , Jan. 14, 2014  Organovo ... institutes from the National Institutes of Health (NIH) to ... more effective treatments to patients on a faster timeline. ... Translational Sciences (NCATS) and the National Eye Institute (NEI) ...
(Date:1/14/2014)... 14, 2014  RXi Pharmaceuticals Corporation (OTCQX: RXII), a ... innovative therapies addressing major unmet medical needs using ... Notice of Allowance from the United States Patent ... compounds (sd-rxRNA®), for the treatment of fibrosis. The ...
Breaking Biology Technology:Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3
... subsidiary in Philadelphia Area -, PHILADELPHIA, Feb. ... cellular imaging, announced today the appointment of Chris ... subsidiary of Paris-based Mauna,Kea Technologies and develops and ... improves patient care by eliminating the,need for unnecessary ...
... Prescription Rates, According ... to a New Report from Decision Resources, WALTHAM, ... leading research and advisory firms focusing on pharmaceutical and,healthcare ... ustekinumab will become the clinical gold standard,for psoriasis by ...
... the world,s leading,online bioscience job board and life ... pharmaceutical job candidates at its Biotech,Bay Career Fair ... The BioSpace Career Fair drew a steady ... career candidates from,around the Northern California region. For ...
Cached Biology Technology:Chris Tihansky Appointed President of In Vivo Cellular Imaging Leader Cellvizio Inc. 2Centocor/Janssen-Cilag's Ustekinumab Will Become the Gold Standard for Psoriasis By 2011 2BioSpace Career Fair in San Francisco Welcomes Over 1,000 Bioscience Professionals 2
(Date:4/22/2014)... London PETA International Science Consortium Ltd.,s nanotechnology expert ... strategy for nanomaterial hazard assessment" at the 7th ... 2014, in Antalya, Turkey. , Dr. Monita Sharma ... from the US National Academy of Sciences, " Toxicity ... Strategy ," which recommends use of non-animal methods involving ...
(Date:4/22/2014)... nanotechnology researchers at the University of Kentucky has discovered ... using RNA. , The research, led by Peixuan ... Nanobiotechnology at the UK College of Pharmacy and Markey ... as a Boiling-Resistant Anionic Polymer Material To Build Robust ... F. Khisamutdinov and Daniel L. Jasinski. , The article, ...
(Date:4/22/2014)... and precipitation on the global distribution of plant and ... the UV-B radiation, is often neglected. The landscape ecologists ... Universities in Olomouc (Czechia), Halle and Lneburg have processed ... such a way that they can be used to ... The basic input data were provided by a NASA ...
Breaking Biology News(10 mins):RNA shows potential as boiling-resistant anionic polymer material for nanoarchitectures 2UV-radiation data to help ecological research 2
... in Uganda who self-paid for their antiretroviral medications experienced ... or supply logistical disruptions. These treatment interruptions led ... patients. , These findings by a team led by ... Kampala, and UCSF are reported in the April 22, ...
... pediatric specialists at Baylor College of Medicine have discovered a ... that allows drugs to enter cancer cells. , The research ... and Biomolecular Chemistry. , All living cells defend themselves ... form a protective cocoon around the cell's inner machinery and ...
... cells to turnover their contents, something that they do ... and radiation, but it is not known if this ... survive the anti-cancer therapy. However, in a study using ... the University of Pennsylvania have now shown that autophagy ...
Cached Biology News:Resistance to anti-HIV drugs in Uganda developed due to drug supply problems 2Buckyballs used as 'passkey' into cancer cells 2
Recombinant Viral CCI/Fc Chimera, CF...
... DeStreak Reagent, 1 ml. ... 2-D gels by preventing streaking.Eliminates ... oxidation of proteins.Stabilizes proteins throughout ... simplified, well-resolved protein patterns.Ideal for ...
LIVE/DEAD® Cell-Mediated Cytotoxicity Kit *for animal cells* *2000 assays*...
SlowFade Antifade Kit with DAPI...
Biology Products: